Merck & Co. Inc.
(NYSE:MRK) on Monday announced results from two late-stage clinical studies evaluating treatments for advanced or recurrent endometrial cancer at the European Society for Medical Oncology Congress 2026. The drugmaker reported statistically significant survival improvements for both its investigational antibody-drug conjugate, sacituzumab tirumotecan, and its established immunotherapy, Keytruda.
TroFuse-005 Delivers Survival Gains In Endometrial Cancer In the Phase 3 TroFuse-005 study, developed alongside Kelun-Biotech, sacituzumab tirumotecan met its dual primary endpoints in patients previously treated with platinum-based chemotherapy and immunotherapy. Read Also: Merck Discontinues Bacterial Infection Drug in Europe The trial marks the first global Phase 3 study for an antibody-drug conjugate to demonstrate statistically significant survival gains over chemotherapy in this population.
1 months. 9 months.
3%. The safety profile remained consistent with earlier evaluations without new safety signals.
S. Food and Drug Administration accepted a Biologics License Application under priority review, with a decision date of June 15, 2027.
KEYNOTE-C93 Demonstrates Keytruda Monotherapy Efficacy Simultaneously, Merck highlighted results from the Phase 3 KEYNOTE-C93 trial assessing Keytruda monotherapy in patients with mismatch repair deficient endometrial cancer. Keytruda lowered the risk of disease progression or death by 43% compared to platinum doublet chemotherapy.
4 months for chemotherapy recipients. 0% for chemotherapy.
2% for chemotherapy, while researchers identified no new safety concerns. 82 at the time of publication on Monday, according to Benzinga Pro data.
